Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 3 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 27 % of short-term debt in 2024; threshold 65 %.
-
Late annual account NBB
Fiscal year 2024 was filed 195 days after the legal deadline.
-
Busy address KBO
27 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
Neuraxpharm Belgium from Sint-Joost-ten-Node, company number BE0793136336, closed financial year 2024 with a result of € -143,209 after tax. For that financial year Neuraxpharm Belgium recorded a gross margin of € -34,758 and equity of € -595,385. Compared with financial year 2023, the result moved from € -436,979 to € -143,209. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on February 11, 2026.
€ -595,385
▼ € 143,209 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -143,209
▲ 67 % less loss than in 2023
Profit after tax over the fiscal year.
€ 364,299
▲ 286% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -600,385.
People and assets in 2024
0.7
Average over the fiscal year, from the social balance sheet.
€ 131,625
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 5,968
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 2.3 million
▲ 91% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 223,525
▲ € 213,116 vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|
| Gross margin | € -20,197 | € -193,684 | € -34,758 | ▲ € 158,926 |
| Profit after taxes | € -20,197 | € -436,979 | € -143,209 | ▲ € 293,770 |
| Equity | € -15,197 | € -452,176 | € -595,385 | ▼ € 143,209 |
| Total debts | € 20,810 | € 1,461,654 | € 2,480,180 | ▲ 70% |
| Cash | € 5,000 | € 94,307 | € 364,299 | ▲ 286% |
| Retained profit | € -20,197 | € -457,176 | € -600,385 | ▼ € 143,209 |
| Balance sheet total | € 5,614 | € 1,009,478 | € 1,884,796 | ▲ 87% |
| Employees (FTE) | - | - | 0.7 |
Key figures of Neuraxpharm Belgium, fiscal years 2022 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Neuraxpharm Belgium?
What happened at Neuraxpharm Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 143,209. filed late Source: NBB ↗
- Pierre Hervé BRUN became a director. NBB
- Michaël Lugez stepped down as director. NBB
- Michaël Lugez became a director. NBB
- New establishment in Sint-Joost-ten-Node. KBO
- Start of the company according to the CBE. KBO
- Maximilian VON WULFING became a director. NBB
In short
From € 20,197 loss in 2022 to € 143,209 loss in 2024.
A new publication or filing at Neuraxpharm Belgium? We notify you, reason included.
Follow Neuraxpharm BelgiumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Neuraxpharm Belgium are Maximilian VON WULFING and Pierre Hervé BRUN. The shares are held by Neuraxpharm Arzneimittel GmbH (100%).
Directors
According to the 2024 annual accounts
Maximilian VON WULFING
Director
since 2022
Pierre Hervé BRUN
Director
since 2025
Michaël Lugez
Director
since 2024 · until 2025
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Sint-Lazaruslaan 4/10
1210 Sint-Joost-ten-Node
Sint-Lazaruslaan 4-10 ET6
1210 Sint-Joost-ten-Node
Active since 28 October 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 27 companies are registered at this address.
All companies at this address →QUICK RESTAURANTS
€ 6 million revenue · 2025
FUBON ELLIPSE( BELGIUM)
€ 29,146 revenue · 2025
FORS MANAGEMENT
€ -17,803 gross margin · 2025
TATA COMMUNICATIONS (BELGIUM)
€ 88,412 gross margin · 2026
IMMO DE MEEUS
€ 3.2 million revenue · 2025
+22 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0793.136.336
- VAT number
- BE 0793.136.336
- Registered office
- Sint-Lazaruslaan 4/10, 1210 Sint-Joost-ten-Node
- Names & denominations
- Neuraxpharm Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 October 2022
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen